Your session is about to expire
← Back to Search
PSMA PET/CT Scan for Prostate Cancer
Phase 3
Waitlist Available
Led By Geoffrey B Johnson
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up after imaging scan is complete - up to 1 day
Awards & highlights
Study Summary
This trial offers access to PET/CT scans to detect prostate cancer in patients with metastatic castrate-resistant prostate cancer, using a small amount of radioactive tracer (68Ga-PSMA-11) that binds to the cancer cells.
Who is the study for?
This trial is for adult men with metastatic castrate-resistant prostate cancer who are under care at Mayo Clinic and considered for PSMA-targeted radionuclide therapy. They must not have had a reimbursable 68Ga-PSMA-11 PET scan, be above 18 years old, and able to consent and remain still during imaging.Check my eligibility
What is being tested?
The study tests the use of a radioactive tracer in PET/CT scans to detect prostate cancer lesions. It involves using Gallium Ga 68 Gozetotide (68Ga-PSMA-11) which attaches to cancer cells, combined with CT imaging to screen patients before they receive targeted radionuclide therapy.See study design
What are the potential side effects?
Potential side effects may include reactions related to the injection of the radioactive tracer such as mild pain or discomfort at the injection site. The radiation exposure from PET/CT is low but carries a small risk of contributing to future cancer risk.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ after imaging scan is complete - up to 1 day
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~after imaging scan is complete - up to 1 day
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Gallium
Trial Design
1Treatment groups
Experimental Treatment
Group I: Observational (68Ga-PSMA-11 PET/CT)Experimental Treatment3 Interventions
Patients receive 68Ga-PSMA-11 IV and then undergo a PSMA PET/CT scan throughout the trial.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Computed Tomography
2017
Completed Phase 2
~2720
Gallium Ga 68 Gozetotide
2020
Completed Phase 3
~1750
Positron Emission Tomography
2008
Completed Phase 2
~2240
Find a Location
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,207 Previous Clinical Trials
3,766,977 Total Patients Enrolled
34 Trials studying Prostate Cancer
8,388 Patients Enrolled for Prostate Cancer
National Cancer Institute (NCI)NIH
13,658 Previous Clinical Trials
40,924,326 Total Patients Enrolled
561 Trials studying Prostate Cancer
507,113 Patients Enrolled for Prostate Cancer
Geoffrey B JohnsonPrincipal InvestigatorMayo Clinic in Rochester
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Research Study Groups:
This trial has the following groups:- Group 1: Observational (68Ga-PSMA-11 PET/CT)
Awards:
This trial has 2 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any opportunities for individuals to enroll in this experiment currently?
"Unfortunately, this clinical trial is not recruiting as of February 15th 2023. The first post was on May 9th 2022, and there are currently 3633 other studies actively looking for patients."
Answered by AI
To what extent could the utilization of Observational (68Ga-PSMA-11 PET/CT) be detrimental to human health?
"Taking into account the clinical evidence and numerous safety studies, our experts at Power have evaluated Observational (68Ga-PSMA-11 PET/CT) as a 3 on their scale of 1 to 3."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger